Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Assets (2020 - 2026)

PROCEPT BioRobotics has reported Assets over the past 7 years, most recently at $487.1 million for Q1 2026.

  • Quarterly Assets fell 6.22% to $487.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $487.1 million through Mar 2026, down 6.22% year-over-year, with the annual reading at $508.1 million for FY2025, 4.86% down from the prior year.
  • Assets was $487.1 million for Q1 2026 at PROCEPT BioRobotics, down from $508.1 million in the prior quarter.
  • Over five years, Assets peaked at $534.0 million in Q4 2024 and troughed at $272.4 million in Q2 2023.
  • The 5-year median for Assets is $382.9 million (2024), against an average of $403.1 million.
  • Year-over-year, Assets dropped 12.38% in 2023 and then soared 37.4% in 2024.
  • A 5-year view of Assets shows it stood at $309.3 million in 2022, then soared by 30.84% to $404.7 million in 2023, then soared by 31.95% to $534.0 million in 2024, then fell by 4.86% to $508.1 million in 2025, then fell by 4.14% to $487.1 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Assets are $487.1 million (Q1 2026), $508.1 million (Q4 2025), and $511.5 million (Q3 2025).